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2ABSTRACT
Niacinamide (NIA) has been widely used in cosmetic and personal care formulations for 
several skin conditions. Permeation of topical NIA has been confirmed in a number of studies 
under infinite dose conditions. However, there is limited information in the literature 
regarding permeation of NIA following application of topical formulations in amounts that 
reflect the real-life use of such products by consumers. The aim of the present work was 
therefore to investigate skin delivery of NIA from single solvent systems in porcine skin 
under finite dose conditions. A secondary aim was to probe the processes underlying the 
previously reported low recovery of NIA following in vitro permeation and mass balance 
studies.  The solubility and stability of NIA in various single solvent systems was examined. 
The solvents investigated included Transcutol® P (TC), propylene glycol (PG), 1-2 
hexanediol (HEX), 1-2 pentanediol (1-2P), 1-5 pentanediol (1-5P), 1-3 butanediol (1-3B), 
glycerol (GLY) and dimethyl isosorbide (DMI). Skin permeation and deposition of the 
molecule was investigated in full thickness porcine skin in vitro finite dose Franz-type 
diffusion experiments followed by mass balance studies. Stability of NIA for 72 h in the 
solvents was confirmed. The solubility of NIA in the solvents ranged from 82.9 ± 0.8 to 
311.9 ± 4.5 mg/mL. TC delivered the highest percentage permeation of NIA at 24 h, 32.6 ± 
12.1 % of the applied dose. Low total recovery of NIA after mass balance studies was 
observed for some vehicles, with values ranging from 55.2 ± 12.8 % to 106.3 ± 2.3 %. This 
reflected the formation of a number of NIA degradation by-products in the receptor phase 
during the permeation studies. Identification of other vehicles for synergistic enhancement of 
NIA skin delivery will be the subject of future work.
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31. Introduction
Niacinamide (NIA) also termed nicotinamide is a water-soluble vitamin that has been 
used in a range of topical formulations (Cosmetic Ingredient Review Expert Panel, 2005). 
The molecule is naturally found in human cells as a precursor of the co-dehydrogenases NAD 
and NADP and participates in several biological oxidation – reduction reactions. NIA has 
been reported to demonstrate various effects in vitro, namely (i) increased cellular DNA 
synthesis (ii) repair of UV-induced DNA damage in human melanocytes (iii) promotion of 
synthesis of ceramides, free fatty acids and cholesterol in cultured human keratinocytes (iv) 
inhibition of melanosome transfer from melanocytes to keratinocytes in co-cultured cells and 
(v) decreased IL-8 production and inhibition of P. acnes induced inflammatory responses of 
human keratinocytes (Tanno et al., 2000; Hakozaki et al., 2002; Grange et al., 2009; 
Thompson et al., 2014). 
The actions of NIA on human skin health have also been investigated in a number of in 
vivo studies. Crowther et al. (2008) used confocal Raman spectroscopy to measure the 
stratum corneum (SC) thickness and water content of the forearm of 14 human subjects after 
application of various emollient formulations twice daily for 2 weeks, one of which contained 
NIA. The NIA-containing formulation significantly increased SC thickness and hydration 
compared with other treatments and the control (untreated site). A later in vivo study was 
conducted by Mohammed et al. (2013) for 28 days. Formulations containing 5 % NIA as well 
as control formulations were applied twice daily on the forearms of 20 volunteers. At the end 
of the study areas treated with niacinamide showed decreased trans-epidermal water loss 
(TEWL) and increased SC thickness, larger and more mature corneocytes as well as 
decreased inflammatory activity. 
 In a more recent clinical study, Nisbet et al. (2019) investigated the changes in facial 
redness of 59 female participants with winter xerosis-associated skin erythema. The study 
included two test treatment groups with volunteers that applied two different NIA 
formulations twice daily for 28 days. The researchers found a statistically significant 
reduction in facial redness for both groups after 15 days compared with a baseline. They also 
reported that after 29 days of treatment the level of efficacy was greater for subjects with 
severe erythema compared with those with moderate facial redness. Topical application of 
NIA has also been reported to have a role in reduction of sebum production (Draelos et al., 
42006). Recently, Caetano et al. (2019) conducted an in vivo study to examine the effects of a 
topical formulation containing NIA in female subjects. A significant reduction in both papule 
and pustule count and appearance after 8 weeks was reported for the group that used the NIA-
containing product compared with the control. Finally, the ability of NIA to reduce the 
appearance of hyper-pigmentation has also been reported in vivo. Navarrete-Solis et al. 
(2011) examined the depigmentation effect of topical NIA on 27 female patients’ facial skin 
with melasma over an 8-week period. The patients applied a NIA formulation on one side of 
their face and a hydroquinone preparation on the other side. Hydroquinone is an established 
ingredient for skin whitening (Jimbow et al., 1974) and treatment with NIA resulted in 
similar whitening effects on the hyper-pigmented areas of the skin as hydroquinone.
Although NIA is a hydrophilic compound with a logP(o/w) value of -0.35 (Haque et al., 
2017a), the ability of the molecule to penetrate the skin after topical application has been 
confirmed by several in vitro studies using human or porcine skin (Cosmetic Ingredient 
Review Expert Panel, 2005; Mohammed et al., 2014; Haque et al., 2017a; Zhang et al., 
2019a). However, there is only limited information with regards to skin permeation of NIA 
using finite doses of formulations (Haque et al., 2017a; Zhang et al., 2019a). Where such 
studies have been conducted, low recovery of NIA was also observed following mass balance 
studies (Haque et al., 2017a; Zhang et al., 2019a). Although this has recently been 
investigated using pseudo-finite and infinite dose models (Sil et al., 2018), evaluation of the 
potential degradation process has not been examined under finite dose conditions. The aims 
of the present work were therefore (i) to investigate the skin delivery of NIA in vitro in 
porcine skin from a range of single solvents under finite dose conditions and (ii) to utilise 
LC-MS in order to gain insight into the processes underlying the low recovery of NIA in 
these studies. 
2. Materials and methods 
2.1.  Materials 
NIA, 1-2 propanediol (PG), 1-2 pentanediol (1-2P), 1-5 pentanediol (1-5P), 1-2 hexanediol 
(HEX), 1-3 butanediol (1-3B), dimethyl isosorbide (DMI), dipropylene glycol (DiPG) and 
glycerol (GLY) were supplied by Sigma Aldrich (Dorset, UK). Methanol and water hyper 
grade for LC-MS, LiChrosolv® were also obtained from Sigma-Aldrich (Dorset, UK). 
5Transcutol® P (TC) was a kind donation from Gattefossé (St. Priest, France). High 
Performance Liquid Chromatography (HPLC) grade water and methanol were purchased 
from Fisher Scientific (Leicestershire, UK). Phosphate-buffered saline (PBS) tablets were 
purchased from Oxoid Limited (Cheshire, UK). Full thickness porcine ear skin was obtained 
from a local abattoir from healthy animals farmed for food chain purposes.
2.2.  Methods
2.2.1. HPLC analysis and method validation 
The analysis of NIA was performed using an HPLC system of 1260 series (Agilent 
Technologies, Santa Clara, CA, USA), equipped with a Luna® reverse phase column, 250 x 
4.60 mm, 5 μm, Phenyl-Hexyl (Phenomenex, Macclesfield, UK) and a universal HPLC guard 
column (Phenomenex, Macclesfield, UK) packed with a SecurityGuardTM cartridge 
(Phenomenex, Macclesfield, UK). The analytical method as described previously (Haque et 
al., 2017a) was optimised and validated for the parameters of linearity, range, precision, 
accuracy, limit of detection (LOD), limit of quantitation (LOQ) (International Council for 
Harmonisation, 2005). The mobile phase consisted of methanol:water (20:80). The UV 
detector was set to 263 nm, the flow rate to 1 mL/min and the column temperature to 30o C. 
The injection volume was 10 μL. A calibration curve ranging from 0.5 to 200 µg/mL was 
constructed. The validation parameters of accuracy, precision, inter-day variability and intra-
day repeatability were determined as described previously (Iliopoulos et al., 2019). 
2.2.2. Dynamic vapour sorption studies 
A dynamic vapour sorption (DVS) apparatus, TGA Q5000 SA (TA Instruments, New Castle, 
DE, USA) was used to study the mass differences due to evaporation or hydration of the 
examined formulations. Metallised quartz pans connected to a microbalance accurate to 0.1 
% of the measured weight were used to evaluate the mass variations. Temperature and 
relative humidity (RH) were controlled throughout the experiment at 32 ± 0.5 °C and 50 ± 2 
% RH, respectively. 5 µL of formulation were placed in the sample pan for 24 h, i.e. 
solutions of NIA (3 % w/w) in PG, 1-2P, 1-5P, 1-3B, GLY, DMI, DiPG and TC. Data were 
recorded using Universal Analysis 2000 v. 4.5A (TA Instruments, New Castle, DE, USA)
62.2.3. Solubility parameter, solubility and stability studies 
The solubility parameters (δ) of both the actives and solvents were estimated by the Van-
Krevelen and Hoftyzer method using Molecular Modelling Pro® software (Version 7.0.8, 
Norgwyn Montgomery Software Inc., North Wales, PA, USA, 2016). The solubility 
parameters are defined as the sum of all the cohesive forces of a material. The Van Krevelen 
and Hoftyzer approach has been used for rational selection of excipients in pharmaceutical 
formulations and good correlation between theoretical predictions and experimental findings 
has been reported (Shah and Agrawal, 2013). Saturation solubility determinations were 
conducted as reported previously: excess NIA was added to each solvent mixture in 
Eppendorf® tubes in triplicate. Tubes were placed in a shaking incubator (Orbital Mini 
shaker, VWR International Limited, Leicestershire, UK) for 48 h at 32 ± 1o C and were 
subsequently centrifuged for 15 min at 10,000 rpm and 32o C in an Eppendorf 5415R 
centrifuge (Eppendorf, Hamburg, Germany). The supernatant liquid was diluted as necessary 
to lie within the analytical range of the HPLC method (Iliopoulos et al., 2019). Stability of 
NIA in the solvents was investigated for 72 h (3 d) at 32 ± 1o C. Solutions of NIA 3 % (w/w) 
were prepared in triplicate and placed in an Eppendorf ® tube. The sample was sealed with 
Parafilm® (Bemis Inc., U.S.A.) and placed in a shaking incubator, as for solubility studies. 
Samples were collected at 0, 24, 48, and 72 h. All samples were diluted and analysed by 
HPLC. 
2.2.4. Finite dose permeation and mass balance studies
NIA solutions (3 % w/w) were prepared, as formulations of this concentration have 
previously shown effective permeation through skin (Haque et al., 2017a). The permeation 
studies were conducted using vertical glass Franz-type diffusion cells and full thickness 
porcine ear skin according to procedures reported previously (OECD, 2004a, b; Haque et al., 
2017b; Iliopoulos et al., 2019). Freshly prepared PBS (pH 7.3 ± 0.2) was used as the receptor 
solution. Finite doses of 5 μL of the test solution were applied to the donor compartment 
which was not occluded. A volume of 200 μL of receptor solution was collected at 0, 15 min, 
30 min, 45 min, 1 h, 2 h, 5 h, 8 h, 10 h, 12 h and 24 h, and an equal volume of PBS solution 
was added to the receptor compartment. All samples were analysed using HPLC. The number 
of replicate experiments was n ≥ 4. After the 24 h permeation study, a mass balance study 
7was also conducted as described previously (Haque et al., 2017a). The skin surface was 
washed and the skin membranes were extracted with 1 mL of water:methanol (50:50) to 
quantify the amount of NIA on the surface and inside the skin respectively. The skin samples 
were centrifuged for 1 min at 13,000 rpm at 32o C in an Eppendorf 5415R centrifuge 
(Eppendorf, Hamburg, Germany) and subsequently they were extracted by incubation in an 
orbital shaker (Orbital Mini shaker, VWR International Limited, Leicestershire, UK) at 32o C 
overnight. Subsequently, all samples were centrifuged at 13,000 rpm at 32o C for 20 min, the 
supernatant solution was collected and analysed using the HPLC analytical method.
2.2.5. Identification of NIA degradation by-products following in vitro 
skin permeation studies
The analysis of NIA and NIA by-products was conducted as described by Sil et al. 
(2018). Briefly, at the end of the permeation study, the receptor solution was collected and 
freeze-dried using a Thermo Scientific Heto Power dry LL1500 manifold freeze dryer 
equipped with a RC 6 chemistry-HYBRID rotary high vacuum pump (Vacuubrand®, 
Brackley, UK) and condenser temperature set at -113°C. Potential NIA by-products were 
extracted from the dry residue with water:methanol (50:50) and the samples were analysed by 
LC-MS. Subsequently, semi-preparative LC was performed to isolate the unknown peak with 
a retention time 4.6 min (Figure S1), which was further investigated with accurate mass 
analysis. The LC-MS analysis of the samples was conducted using an Agilent Infinity II 1260 
(Agilent Technologies, Cheshire, UK) system equipped with an Agilent G7129A vial 
sampler, G7111B quaternary pump and G7114A variable wavelength detector coupled to a 
single quadrupole mass spectrometer Agilent Infinity Lab LC-MSD XT. The parameters for 
the mass spectrometry analysis were the same as those reported by Sil et al. (2018), and the 
conditions were the same as for the HPLC method. For the semi-preparative LC, a sample 
volume of 100 µL was injected. High-resolution mass spectra were carried out using either a 
Kratos MS89MS with Kratos DS90 software or a Jeol AX505W with Jeol complement data 
system. Samples were ionised electronically (EI), with an accelerating voltage higher than 6 
kV or by low resolution fast atom bombardment (FAB) in a thioglycerol matrix. 
2.2.6. Data analysis
8The data was analysed using Microsoft® Excel 2013 software (Microsoft 
Corporation, Redmond, Washington, USA) and GraphPad Prism Statistics software (version 
8.3.0, San Diego, CA, USA, 2019). Results are presented as the mean ± standard deviation 
(SD). The normality of the data was assessed using the Shapiro-Wilk test. For parametric 
data, the independent-samples t-test as well as one-way analysis of variance (ANOVA) with 
Tukey’s HSD post hoc test were used to analyse two groups and ≥ 3 groups respectively. For 
non-normally distributed data or where variances were not equal, the Kruskal-Wallis and 
Mann-Whitney U Tests and independent sample t-test were used, respectively. Statistical 
significance was assumed when the p value was less than 0.05.
3. Results and discussion
3.1. HPLC method validation
A correlation coefficient value (r2) greater than 0.99 was obtained, thereby indicating 
an acceptable fit to the regression line (Shabir, 2003). The retention time of NIA was 5.2 ± 
0.1 min. The accuracy was 100.2 ± 0.5 %. The % RSD values for inter-day and the intra-day 
precision were 0.29 ± 0.19 % and 0.26 ± 0.19 %, respectively. The LOD value was 0.15 
µg/mL and the LOQ was 0.47 µg/mL.
3.2. Solubility and stability of NIA in candidate vehicle
The saturation solubility values of NIA in the solvents investigated are shown in Fig. 
1. The calculated solubility parameters of vehicles are also shown. The solubility parameter 
of NIA was calculated as 13.9 ((cal/cm3)1/2). NIA solubility in the solvents ranged from 82.9 
± 0.8 to 311.9 ± 4.5 mg/mL (Figure 1). Solubility of NIA was found to be higher in the 
solvents with solubility parameter values closer to that of NIA. This observation is consistent 
with other reports in the literature (Mohammed et al., 2014; Zhang et al., 2019a). NIA 
demonstrated stability in all solvents, with recovery values > 85 % after 72 h, as shown in 
Fig. S2.
3.3. Dynamic vapour sorption studies
9Fig. 2 shows the DVS results for all NIA 3 % (w/w) single solvent solutions over 24 h 
at 32 ± 0.5 °C and 50 ± 2 % RH. The most volatile solvent was found to be TC and only 6.3 
% of the initial dose was recovered at 24 h. For PG, 52.9 % of the applieS2d mass was 
recovered at 24 h. 26.7 % and 21.7 % of the applied DMI and 1-2P respectively evaporated. 
Only 5% of the applied DiPG evaporated during the experiment. For all solvents, an initial 
increase of weight was found because of their hygroscopic nature. No evaporation was 
evident for the GLY and 1-5P formulations. These findings are consistent with previous 
reports on the evaporation of neat GLY, DMI, PG and TC (Haque et al., 2017b; Zhang et al., 
2019b). To our knowledge DVS has not been used previously to characterise the behaviour of 
NIA solutions under controlled conditions of temperature and humidity. DVS results for the 
neat solvents suggest that both PG and TC will evaporate to a much greater extent compared 
with the other solvents after 24 h, as shown in the Figure 2. 
3.4. Permeation studies using neat solvents
Finite dose permeation studies of NIA were performed using GLY, DiPG, PG, HEX, 1-
2P, 1-5P, 1-3B, DMI and TC. All permeation studies were conducted for 24 h with samples 
(200 μL) taken at different time points (t = 0, 15 min, 30 min, 1h, 2h, 5h, 8h, 10h, 12h and 
24h). A dose of 5 μL of each formulation was applied on the surface of the skin. Permeation 
of NIA was evident for all solvents, as shown in Figure 3. For NIA to exert its actions as 
described in the introduction above, it must reach the viable layers of the skin. The 
cumulative permeation of an active in vitro is an indicator of the effectiveness of the 
respective formulations, in terms of promoting its delivery to the skin under real conditions in 
vivo, as demonstrated in previous studies (Mateus et al., 2014; Mohammed et al., 2014).
The highest percentage permeation of NIA after 24 h was from TC, comprising 32.6 ± 
12.1 % of the applied dose. This value was not significantly different from that for PG (19.2 
± 16.3%, p > 0.05), but significantly higher than for all other solutions investigated (p < 
0.05). Even though the mechanism by which TC interacts with the skin is not known, its 
potential to act as a penetration enhancer has been reported for a number of compounds 
(Lane, 2013). Puglia and Bonina (2008) investigated the effect of several commonly used 
enhancers on the permeation of atenolol in human skin in vitro. The authors prepared five 
emulsions, each containing a different penetration enhancer and reported that the TC 
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containing formulations resulted in the highest drug absorption. This was attributed to the 
ability of TC to penetrate SC and increase solubilisation of active inside the skin. More 
recently, Haque et al. (2017b) used gas chromatography to measure percutaneous absorption 
of solvents in vitro and found that TC permeated through human skin in significantly higher 
quantities compared with other solvents following finite dosing. In addition, the volatile 
nature of the solvent TC has been reported previously (Haque et al., 2017b) and the 
evaporation of NIA-containing TC formulations was confirmed experimentally in the present 
study (Figure 2). Depletion of the solvent from the skin surface can increase the 
thermodynamic activity of the active in the vehicle, and it is likely to result in enhancement 
of percutaneous absorption. This hypothesis has been examined by Oliveira et al. (2012) who 
conducted in vitro finite dose permeation studies in human skin using different vehicles with 
and without ethanol. Formulations containing ethanol were reported to result in increased 
penetration of the active compound, which was attributed to partial evaporation of the 
formulations leaving a highly concentrated residue on the skin surface. In the present study, 
we found that 93.7 % of the initial mass of the NIA in TC solution had evaporated after 24h 
(Figure 2). The evaporation of the formulations as examined by DVS and shown in Figure 2 is 
not expected to be the same as when the formulations are applied to the skin in a Franz cell. 
Specifically, unlike the conditions in the DVS chamber, where a constant flow of nitrogen is 
present to maintain the desired relative humidity, the donor chamber of a Franz cell may inhibit 
the air movement, thereby decreasing the evaporation rate of the volatile compounds (Reifenrath 
et al., 1991). Additionally, permeation of the solvents and the active inside the skin can lead to a 
decrease of the residue on the upper skin layer and this cannot be estimated by the DVS studies. 
However, despite these limitations, it is clear that TC is a volatile solvent and notable amounts of 
this vehicle will evaporate from the skin surface over 24 h. Even though TC does not evaporate 
as rapidly as ethanol (Oliveira et al., 2012), the dynamic nature of the TC preparation is likely 
to promote similar enhancing effects on delivery of NIA over a 24 h period.
PG is a hydrophilic solvent that has been used in topical formulations as a solvent for 
many actives (Lane, 2013; Haque et al., 2017b; Haque et al., 2018; Paz-Alvarez et al., 2018; 
Hossain et al., 2019; Iliopoulos et al., 2019; Zhang et al., 2019b).  In the present work, 5 μL 
doses of 3 % (w/w) NIA in PG were applied to porcine skin and the percentage permeation 
after 24 h was 19.2 %. These data are consistent with a recent report from our group, where 
19.5 % of the dose of NIA permeated across pig skin after a finite dose application of 5 % 
(w/v) NIA in PG (Zhang et al., 2019a). The mechanism of action of PG has not been fully 
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understood, however, it is believed that it penetrates the SC and increases the solubility of the 
active in the skin (Williams and Barry, 2012; Lane, 2013). Permeation of PG through human 
skin has been confirmed in a number of in vitro studies. Trottet et al. (2004) conducted Franz-
type experiments using gel formulations containing PG and found that the percentage 
permeation of PG was approximately 30% when finite doses of the formulations were 
applied. In a later study, Haque et al. (2017b) applied similar amounts of neat PG to human 
skin in vitro and reported that 13 % of the applied solvent had permeated at 24 h. In an in 
vivo study, Mohammed et al. (2014) monitored the penetration of NIA and various solvents 
across the SC using confocal Raman spectroscopy. These authors noted that penetration of 
NIA was correlated with the depth of penetration of the PG, indicating the ability of PG to 
“carry” the active as it diffuses across the skin. In the present work, PG was the only solvent 
that promoted NIA permeation to the same extent as TC (p > 0.05). 
DiPG is a hydrophilic oligomer of PG, that has been widely used in skin formulations 
(Cosmetic Ingredient Review Expert Panel, 1985), but its effect on the skin barrier has not 
been studied in detail.  Fasano et al. (2011) investigated the permeation of both PG and DiPG 
across human abdominal skin using infinite dose in vitro studies under occlusion. The 
researchers also measured the skin impedance before and after the experiments. DiPG was 
reported to have no effect on the impedance values after 24 hours of skin exposure, while PG 
caused a significant decrease in impedance. DiPG was reported to have a 2.5 fold lower 
steady state permeation flux than PG under these conditions. Lower skin permeation of DiPG 
than PG was also reported by Haque et al. (2017b) following finite dose permeation studies in 
human skin. The percentage permeation of DiPG was reported to be 2.6 % at 24 h and 8 % at 
48 hours, and it was significantly lower than permeation of PG. In the present work, both 
solvents delivered similar amounts of NIA across porcine skin (p > 0.05); however, NIA 
permeation from DiPG was significantly lower than from TC (p < 0.05).
DMI is commonly used as a solubiliser in topical formulations. The exact mechanism 
of its interaction with the skin remains unknown and contrasting reports of its potential to act 
as a penetration enhancer can be found in the literature. Generally, it is believed that this 
solvent can promote topical delivery of hydrophilic compounds by increasing the polarity of 
the SC and therefore promoting drug partitioning in this layer. In an in vivo study, confocal 
Raman spectroscopy was used to monitor the penetration of both DMI and NIA across the 
SC. As for PG, a linear correlation between signal intensity of DMI and the signal intensity of 
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NIA was found (Mohammed et al., 2014). However, in a later study, DMI had no enhancing 
effect on the penetration of hexamidine diisethionate nor its dihydrochloride salt across pig 
skin in vitro (Parisi et al., 2016). In the present work, single solvent systems of DMI resulted 
in cumulative permeation of NIA of 9.8 ± 2.7 μg/cm2, corresponding to 6.1 ± 2.1% of the 
applied NIA. These values were significantly lower than TC (p < 0.05), but comparable with 
all other solvents (p > 0.05). 
The solvent 1-2P is a short chain 1, 2-glycol that is used mainly as a skin conditioning 
and viscosity increasing agent in topical products (Johnson et al., 2012). There is only limited 
information in the literature regarding its action on the skin and its ability to act as a 
penetration enhancer has not been established. Duracher et al. (2009) examined the influence 
of 1-2P on the permeation of caffeine across porcine skin in vitro following finite dose 
application under occlusion. The researchers compared the efficacy of vehicles consisting of 
water and either 1-2P or PG and reported that the 1-2P formulations delivered higher amounts 
of caffeine through the skin. Additionally, the authors prepared formulations of 1-2P:water at 
various ratios and examined their efficacy. The solutions of 1-2P:water (5:95) resulted in 
twice as much penetration of caffeine compared with 1-2P:water (2.5:97.5), indicating that 
the glycol enhanced permeation of caffeine in a dose dependent manner. 
HEX  is a solvent commonly used as a preservative in personal care products because 
of its antibacterial properties (Yogiara et al., 2015). Given its chemical structure, it might be 
assumed that, as for other 1,2 glycols, HEX is likely to penetrate the skin and increase 
permeant solubility in the SC. Lee et al. (2011) conducted a 24 h Franz-diffusion study to 
measure the penetration of various neat 1,2-alkanediols in porcine skin and reported that 
HEX permeated porcine skin at a similar rate as 1-2P. In the present work, permeation of 
NIA was comparable from both HEX and 1-2P solutions (9.4 ± 1.0 and 9.4 ± 1.6 µg/cm2 
respectively, p > 0.05). 
The solvent GLY is widely used in topical products and has been found to improve 
hydration of the skin in a number of clinical studies (Batt and Fairhurst, 1986; Batt et al., 
1988; Pedersen and Jemec, 1999). Even though it has been used mainly as a humectant rather 
than a penetration enhancer, it is believed that increased hydration of the SC can increase 
mobility of the lipids and affect penetration of actives (Zhang et al., 2005). Brinkmann and 
Müller-Goymann (2005) used various techniques, such as differential scanning calorimetry 
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(DSC), wide and small angle X-ray-diffraction (WAXD and SAXD) to investigate the effects 
of GLY on human skin. These authors reported that GLY interacts with SC lipids in a similar 
manner as PG, by integrating between the polar head groups and disordering the skin lipids. 
We recently investigated the effect of GLY on the permeation of the hydrophilic compound 
3-O-ethyl-l-ascorbic acid in porcine skin after finite dosing and found that it resulted in 
similar permeation of the active as for PG (Iliopoulos et al., 2019). In this present work, 
cumulative permeation of NIA from GLY was 7.3 ± 2.4 µg/cm2 after 24h. This value was 
lower than the cumulative permeation of NIA from TC (50.8 ± 19.0, p < 0.05). However, 
GLY delivered comparable amounts of NIA as the other solvents, PG, DMI, 1-2P, 1-3B, 
HEX and 1-5P (p > 0.05). The solvent 1-3B, butylene glycol, has also been used as a solvent 
in many topical formulations (Cosmetic Ingredient Review Expert Panel, 1985). Haque et al. 
(2017b) examined the penetration of this solvent in human skin; 10.3 % of the applied solvent 
permeated the skin after 48 h. In the present work, neat 1-3B resulted in cumulative 
permeation of NIA of 6.1 ± 0.4 μg/cm2, which corresponds to 4.2 ± 0.2 % of the applied NIA. 
1-5P is a short chain alkanediol and its use as a solvent in topical formulations is 
relatively recent. It has been used as an antimicrobial ingredient but its potential to enhance 
topical delivery has not been established (Sundberg and Faergemann, 2008). In a number of 
studies in the literature 1-5P has been reported to enhance penetration of certain lipophilic 
actives in human skin in vitro. Evenbratt and Faergemann (2009) evaluated the effects of 1-
5P and PG on percutaneous delivery of terbinafine. These workers prepared 1% terbinafine 
gel formulations containing various concentrations of either 1-5P or PG and a control 
formulation containing no alkanediol. The researchers proposed that both solvents increased 
permeation of terbinafine compared with the control. They also found that formulations 
containing 5 % 1-5P enhanced topical delivery of the active more effectively than those 
containing 5 % PG.  In later study, Faergemann et al. (2005) investigated the ability of a 
commercial cream containing hexylene glycol and a similar formulation containing 1-5P, to 
promote skin delivery of mometasone furoate. Studies were conducted in human skin using 
continuous flow diffusion studies in vitro. Similar permeation of mometasone furoate from 
both preparations was observed, suggesting that the two solvents had similar enhancing 
effects on percutaneous absorption of the active. With regards to hydrophilic active 
ingredients, however, no penetration of an ethyl derivative of vitamin-C in porcine skin in 
vitro was found when 1-5P was used as a neat solvent (Iliopoulos et al., 2019). The 
contrasting effects of the solvent on the permeation of different actives might be attributed to 
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their different physicochemical properties. It is not known if 1-5P is able to permeate across 
the SC, however, given its hydrophilic nature (logP(o/w) = -0.49 at 25 °C (MSDS, 2019)), it is 
possible that it may not diffuse through the skin, but instead remain in the upper layers of the 
SC. In this work, 1-5P resulted in significantly lower permeation of NIA through pig skin 
compared to TC (p < 0.05). 1-5P delivered similar amounts of NIA (6.1 ± 0.4 µg/cm2) 
compared with the other solvents (p > 0.05). 
The total recovery of NIA after mass balance studies was outside the acceptable range 
of 90 - 110 % for the vehicles TC (55.2 ± 12.8 %), PG (58.9 ± 12.7 %), DMI (69.5 ± 15.3 %), 
1-2P (72.3 ± 10.5 %), DiPG (74.9 ± 11.9 %) and HEX (79.4 ± 18.5 %), as shown in Table I 
(OECD, 2004a, b). The total recovery values observed for 1-5P and GLY, 106.3 and 103.4 % 
respectively, were significantly higher than those for TC and PG (p < 0.05). The percentages 
of NIA recovered for DMI, DiPG, 1-2P and HEX were comparable to values for PG and TC 
(p > 0.05). Low recovery of NIA following finite dose porcine skin permeation studies has 
previously been reported in the literature. Haque et al. (2017a) conducted finite and pseudo-
finite permeation studies in porcine skin using various formulations containing NIA 3 % 
(w/w). The researchers reported that total recovery of NIA after 24 h was lower than 85 % for 
all formulations, indicating partial degradation of NIA. More recently, Zhang et al. (2019a) 
conducted finite dose porcine skin Franz diffusion and mass balance studies using solutions 
of NIA 5 % (w/v) and reported low total recovery values for a number of solvents, including 
PG, TC and DMI. 
3.5. Identification of NIA degradation by-products following in vitro skin 
permeation studies
As noted, a number of pseudo-finite or finite dose porcine skin permeation studies of 
NIA have been reported in the literature for several formulations.  The total NIA recovered in 
mass balance studies fell below the acceptable limits required by OECD guidelines for the 
majority of the solvents used (OECD, 2004a, b; Mohammed et al., 2014; Haque et al., 2017a; 
Zhang et al., 2019a). The findings of the present work are consistent with the previous 
reports. Recently, Sil et al. (2018) investigated this phenomenon using infinite and pseudo-
finite dose in vitro studies in porcine skin with subsequent mass spectrometry analysis and 
suggested that the low recovery reflected chemical derivatisation of the molecule during the 
permeation experiment. The researchers proposed that a reduction pathway of NIA occurred, 
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leading to the formation of several by-products i.e. piperidine-3-carboxamide, 1,4,5,6-
tetrahydropyridine-3-carboxamide and 1,4-dihydropyridine-3-carboxamide. 
In this work, finite doses (5 μL/cm2) of 3 % NIA (w/w) in either TC or PG were 
applied to porcine skin to investigate the low recovery of NIA. Following LC-MS analysis of 
the receptor solution and subsequent characterisation of the mass spectrometry data, the 
compound 1,4,5,6-tetrahydropyridine-3-carboxamide was identified (m/z 127 for M+H, 
Figure 4). The m/z 173 indicates the presence of the ion adduct of this molecule for 
M+H+2Na. The m/z 149 indicates the presence of the M+Na ion of the same compound. A 
value of m/z 171 correlates with the presence of 1,4-dihydropyridine-3-carboxamide for 
M+H+2Na. These findings confirm the occurrence of the proposed NIA reduction pathway as 
described by Sil et al. (2018), where it was proposed that NIA transformed to 1,4-
dihydropyridine-3-carboxamide, subsequently converting to 1,4,5,6-tetrahydropyridine-3-
carboxamide and finally to piperidine-3-carboxamide. In the present work, the piperidine-3-
carboxamide compound was not found in the LC-MS spectrum after the finite dose 
experiments. 
The unknown compound was separated from the sample by semi-preparative LC. 
Subsequently, accurate mass analysis was conducted and the presence of 1,4,5,6-
tetrahydropyridine-3-carboxamide was confirmed. Specifically, the accurate mass analysis 
for NIA and 1,4,5,6-tetrahydropyridine-3-carboxamide is as follows: m/z 123 (100%, 
[M+H]+): Found [M+H]+ 123.0555, C6H6N2O requires 123.0558 and m/z 125 (100%, [M-H]-
): Found [M-H]- 125.0342, C6H10N2O requires 125.0715.
The results of this work identified a number of NIA degradation by-products 
following the finite dose skin penetration studies. These findings confirm the occurrence of a 
reduction pathway of NIA as proposed by Sil et al. (2018). However, the final stage of the 
pathway, namely the formation of the degradant, piperidine-3-carboxamide, was not apparent 
(Figure 5). This could be attributed to the lower doses of NIA employed in the present study 
compared with the infinite or pseudo-finite dose studies performed in the earlier work. The 
formation of these NIA by-products likely explains the low total recoveries observed 
following mass balance studies. 
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4. Conclusions
Topical formulations of NIA have demonstrated a number of beneficial effects on 
skin health and barrier function. This study examined the effect of a number of solvents on 
NIA topical delivery in porcine skin in vitro. Of the solvents studied, TC delivered the 
highest amount of NIA through the skin compared with other solvents with cumulative NIA 
permeation of 50.8 ± 19.0 μg/cm2, corresponding to 32.6 ± 12.1 % of the applied dose. The 
low recovery of NIA after finite dose permeation studies was probed and provided a number 
of insights into the chemical transformation of NIA during penetration. The identification of a 
number of NIA by-products should allow a greater understanding of the fate of NIA in the 
skin. This knowledge will give additional insights into the delivery of NIA inside the skin, 
and will enable a more precise assessment of the efficacy of cosmetic or pharmaceutical 
products on NIA percutaneous delivery. Future studies will focus on additional techniques, 
such as diffusion NMR to separate and quantify the various by-products observed at the end 
of the permeation studies. Subsequently, additional experiments using well-established 
techniques that can assess the skin barrier function, such as trans-epidermal water loss 
(TEWL) and confocal Raman spectroscopy (CRS) will be conducted for investigation of 
potential pharmacological role of these by-products on the skin. Moreover, knowledge of the 
effects of commonly used vehicles on NIA topical delivery will enable synergistic 
combinations of solvents to be selected for future formulation development. Finally, the 
efficacy of complex solvent systems will be investigated and comparisons with commercially 
available products will be investigated. 
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Figure 5 – Niacinamide (NIA) reduction pathway for the formation of its by‐products after finite 
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Table I – Percentage (%) permeation, skin extraction, recovery from skin surface and total recovery of 
niacinamide for neat solvents (mean ± SD, n ≥ 4).
Percentage (%) of applied doseSolvent
% extraction % permeation % washed from the 
surface
% total recovery
GLY 6.0 ± 1.1 4.0 ± 1.3 93.5 ± 8.6 103.4 ± 7.7
PG 16.5 ± 4.2 19.2 ± 16.3 23.2 ± 2.4 58.9 ± 12.7
DiPG 5.6 ± 1.1 6.5 ± 0.9 62.8 ± 12.7 74.9 ± 11.9
1-2P 19.9 ± 2.7 7.9 ± 1.1 44.5 ± 11.9 72.3 ± 10.5
HEX 20.1 ± 6.5 8.2 ± 1.5 51.1 ± 25.5 79.4 ± 18.5
TC 5.1 ± 1.2 32.6 ± 12.1 17.5 ± 0.8 55.2 ± 12.8
1-3B 6.2 ± 0.5 4.2 ± 0.2 86.4 ± 7.5 96.8 ± 8.0
1-5P 5.0 ± 1.0 4.5 ± 0.6 101.8 ± 2.1 106.3 ± 2.3
DMI 4.6 ± 0.6 6.1 ± 2.1 58.8 ± 16.9 69.5 ± 13.3
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